<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bulimia nervosa in adults: Pharmacotherapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bulimia nervosa in adults: Pharmacotherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bulimia nervosa in adults: Pharmacotherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott J Crow, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joel Yager, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1600846"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pharmacotherapy is efficacious for bulimia nervosa and may be included in the treatment regimen as part of multimodal therapy [<a href="#rid1">1-3</a>]. Antidepressants have been most widely studied, and are typically the drugs of choice due to their demonstrated efficacy and tolerability [<a href="#rid2">2,4-10</a>].</p><p>The neurobiology of bulimia nervosa and the mechanism of action for pharmacotherapy are not known [<a href="#rid11">11</a>]. One hypothesis is that central nervous system serotonin pathways are disturbed in at least some patients [<a href="#rid12">12,13</a>].</p><p>Pharmacotherapy for bulimia nervosa is reviewed here. The epidemiology, neurobiology, clinical features, assessment, diagnosis, other treatments and outcome, and medical complications of bulimia nervosa and their management are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2093.html" rel="external">"Eating disorders: Overview of epidemiology, clinical features, and diagnosis", section on 'Bulimia nervosa'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14709.html" rel="external">"Bulimia nervosa in adults: Clinical features, course of illness, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14746.html" rel="external">"Bulimia nervosa in adults: Cognitive-behavioral therapy (CBT)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2094.html" rel="external">"Eating disorders: Overview of prevention and treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14728.html" rel="external">"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management"</a>.)</p><p></p><p class="headingAnchor" id="H537074608"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The core features of bulimia nervosa are binge eating (ie, eating an amount of food that is definitely larger than most people would eat under similar circumstances), inappropriate compensatory behavior to prevent weight gain (eg, self-induced vomiting), and self-evaluation (self-worth) that is unduly influenced by body weight and shape [<a href="#rid14">14</a>]. The diagnostic criteria  (<a class="graphic graphic_table graphicRef91105" href="/z/d/graphic/91105.html" rel="external">table 1</a>) for bulimia nervosa, as well as its clinical features, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14709.html" rel="external">"Bulimia nervosa in adults: Clinical features, course of illness, assessment, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H537075322"><span class="h1">DIFFERENT TREATMENTS AND THEIR EFFICACY</span><span class="headingEndMark"> — </span>Pharmacotherapy is efficacious for bulimia nervosa and may be added to first-line treatment, which consists of nutritional rehabilitation plus psychotherapy [<a href="#rid2">2,3,8</a>]. Nutritional rehabilitation aims to restore a structured and consistent meal pattern, typically three meals and two snacks per day [<a href="#rid2">2</a>]. Cognitive-behavioral therapy and interpersonal psychotherapy can effectively facilitate nutritional rehabilitation. Pharmacotherapy alone is reasonable if specialized nutritional rehabilitation and psychotherapy are not available [<a href="#rid8">8</a>].</p><p>Additional information about nutritional rehabilitation and psychotherapy for bulimia nervosa is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2094.html" rel="external">"Eating disorders: Overview of prevention and treatment", section on 'Bulimia nervosa'</a>.)</p><p class="headingAnchor" id="H88015819"><span class="h2">Pharmacotherapy combined with psychotherapy</span><span class="headingEndMark"> — </span>Combination treatment with pharmacotherapy plus psychotherapy appears to be more efficacious than either treatment alone for treating episodes of bingeing and purging [<a href="#rid8">8,9,15</a>].</p><p class="headingAnchor" id="H88015891"><span class="h3">Compared with psychotherapy alone</span><span class="headingEndMark"> — </span>Combination treatment is more efficacious than psychotherapy alone. A meta-analysis of six randomized trials (257 patients with bulimia nervosa) found that remission occurred in more patients who received combination treatment compared with psychotherapy alone (49 versus 36 percent) [<a href="#rid15">15,16</a>]. However, dropout rates were higher for combination treatment than psychotherapy alone (30 versus 16 percent).</p><p class="headingAnchor" id="H88015898"><span class="h3">Compared with pharmacotherapy alone</span><span class="headingEndMark"> — </span>Combination treatment appears to be more efficacious than pharmacotherapy alone [<a href="#rid9">9</a>]. A meta-analysis of four randomized trials (141 patients with bulimia nervosa) found that remission occurred in more patients who received combination treatment compared with medication alone (42 versus 23 percent); this difference was not statistically significant, but if real, would be clinically meaningful [<a href="#rid15">15,16</a>]. In addition, depressive symptoms improved more with combination treatment. Dropout rates did not differ between combination treatment and pharmacotherapy alone (34 versus 41 percent).</p><p class="headingAnchor" id="H88015905"><span class="h2">Pharmacotherapy alone compared with psychotherapy alone</span><span class="headingEndMark"> — </span>Pharmacotherapy alone appears to be inferior to psychotherapy alone for treating bulimia nervosa [<a href="#rid8">8,9</a>]. A meta-analysis of five randomized trials (237 patients with bulimia nervosa) found that remission occurred in fewer patients who received pharmacotherapy alone compared with psychotherapy alone (20 versus 39 percent); this difference was not statistically significant, but if real, would be clinically meaningful [<a href="#rid15">15,17</a>]. In addition, dropout rates were higher for pharmacotherapy than psychotherapy (40 versus 18 percent).</p><p class="headingAnchor" id="H1600853"><span class="h1">INDICATIONS FOR PHARMACOTHERAPY</span><span class="headingEndMark"> — </span>Pharmacotherapy combined with nutritional rehabilitation and psychotherapy is indicated for treatment of bulimia nervosa, as well as comorbid anxiety disorders and unipolar depressive disorders [<a href="#rid2">2-7,9,18</a>]. However, if nutritional rehabilitation and psychotherapy are not available, pharmacotherapy alone is reasonable, in conjunction with self-help workbooks and educational material for patients and family members to read.</p><p>The clinical features and diagnosis of bulimia nervosa  (<a class="graphic graphic_table graphicRef91105" href="/z/d/graphic/91105.html" rel="external">table 1</a>) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14709.html" rel="external">"Bulimia nervosa in adults: Clinical features, course of illness, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H86984514"><span class="h1">GENERAL PRINCIPLES OF PHARMACOTHERAPY</span></p><p class="headingAnchor" id="H537075155"><span class="h2">Goal of treatment</span><span class="headingEndMark"> — </span>The goal of treatment is remission, ie, abstinence of binge eating and purging. However, many authorities regard a 50 to 75 percent reduction in the frequency of bingeing and purging as a clinically meaningful response to pharmacotherapy [<a href="#rid6">6,19</a>]. Clinicians should regularly monitor patients with residual binge eating and purging because continued symptoms even at substantially reduced levels carry a substantial risk for relapse [<a href="#rid5">5,20</a>].</p><p class="headingAnchor" id="H7762593"><span class="h2">Pretreatment assessment</span><span class="headingEndMark"> — </span>Prior to pharmacotherapy, the clinician should assess the following issues that affect whether and how pharmacotherapy is conducted [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intentions regarding pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>Frequency of binge eating and purging episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Time of day that the patient vomits (if this is the inappropriate compensatory behavior used to prevent weight gain)</p><p class="bulletIndent1"><span class="glyph">●</span>Excessive concern about body weight and shape</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid psychopathology, such as anxiety and depressive disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Sexual functioning</p><p class="bulletIndent1"><span class="glyph">●</span>Psychosocial impairment</p><p></p><p>Patients planning to become pregnant should be referred for first-line treatment with nutritional rehabilitation and psychotherapy, rather than pharmacotherapy. Nutritional rehabilitation, psychotherapy, and the possible teratogenic effects of antidepressants are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2094.html" rel="external">"Eating disorders: Overview of prevention and treatment", section on 'Bulimia nervosa'</a> and  <a class="medical medical_review" href="/z/d/html/89067.html" rel="external">"Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/100334.html" rel="external">"Antenatal use of antidepressants and risks of teratogenicity and adverse pregnancy outcomes: Drugs other than selective serotonin reuptake inhibitors"</a>.)</p><p>The baseline frequency of bingeing and inappropriate compensatory behavior, as well as the level of other psychopathology, provide an index for tracking progress. Medication should be ingested at least 30 minutes prior to vomiting to facilitate absorption. Assessing baseline sexual functioning is helpful to distinguish medication-induced sexual dysfunction from sexual dysfunction that occurs as a symptom of bulimia nervosa.</p><p>The comprehensive assessment of patients with bulimia nervosa is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14709.html" rel="external">"Bulimia nervosa in adults: Clinical features, course of illness, assessment, and diagnosis", section on 'Assessment'</a>.)</p><p class="headingAnchor" id="H7343069"><span class="h2">Adverse side effects</span><span class="headingEndMark"> — </span>To enhance adherence to medications, clinicians should tell patients that adverse side effects may emerge prior to therapeutic effects and that many side effects are transient.</p><p class="headingAnchor" id="H86984773"><span class="h3">Weight change as a side effect</span><span class="headingEndMark"> — </span>Medication-induced weight change is a problem for patients with bulimia nervosa, who by definition focus excessively upon body weight and shape and make inappropriate efforts to lose weight [<a href="#rid14">14</a>]. In discussing weight change as part of informed consent, clinicians should ask patients about their fear of gaining weight, and also explain that cessation of purging does not typically lead to weight gain [<a href="#rid21">21</a>].</p><p>Antidepressants can cause weight gain [<a href="#rid22">22</a>]. Tricyclics and monoamine oxidase inhibitors are more likely to cause weight gain than selective serotonin reuptake inhibitors [<a href="#rid23">23</a>]. Long-term treatment with selective serotonin reuptake inhibitors may result in weight gain, although little or no weight change may be noticed during the first two to three months of therapy [<a href="#rid24">24-30</a>]. In a study of <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, and <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, paroxetine appeared to cause the most weight gain [<a href="#rid31">31</a>].</p><p><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a>, a third-line therapy, can cause weight loss in patients with bulimia nervosa [<a href="#rid32">32,33</a>]. Patients who are obese, overweight, or at the high end of the normal range may welcome the weight loss. However, weight loss is a problem for patients who are underweight or at the low end of the normal range, and in addition, may exacerbate eating disorder psychopathology regarding body weight.</p><p>Additional information about weight change as a side effect of antidepressants and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Weight change'</a> and  <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects", section on 'Antihistaminic'</a> and  <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">"Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"</a>.)</p><p class="headingAnchor" id="H86984566"><span class="h3">Serious side effects</span><span class="headingEndMark"> — </span>Antidepressants may cause serious side effects, including a possible risk of increased suicidality in young adults. <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> may provoke seizures in patients with bulimia nervosa and is contraindicated (see <a class="local">'Avoiding bupropion'</a> below). Monoamine oxidase inhibitors can cause a hyperadrenergic crisis. (See  <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">"Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects", section on 'Safety risks'</a>.)</p><p class="headingAnchor" id="H7761931"><span class="h4">Suicidality</span><span class="headingEndMark"> — </span>Concerns have been raised about an association between antidepressants and suicidality (suicidal ideation, preparatory act, attempt, or death). There may be an age-specific effect, such that antidepressants raise the risk of suicidality in patients aged 18 to 24 years. The potential effect of antidepressants on suicide risk in adults and children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14672.html" rel="external">"Effect of antidepressants on suicide risk in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>.)</p><p class="headingAnchor" id="H483095"><span class="h2">Duration of an adequate trial</span><span class="headingEndMark"> — </span>Based upon clinical experience, a medication that fails to show a satisfactory response (≥50 to 75 percent reduction in the frequency of bingeing and purging episodes) within four to eight weeks should be discontinued and substituted with a new medication. Most randomized trials have lasted six to eight weeks [<a href="#rid6">6</a>].</p><p>For particularly urgent clinical situations, it may be possible to identify within the first few weeks whether the patient is unlikely to respond to a specific medication. Two studies show that lack of meaningful improvement during the first two to three weeks of treatment suggests that the patient will probably not respond to a longer course of treatment (response was defined as at least a 75 percent reduction in the frequency of bingeing and purging).</p><p class="bulletIndent1"><span class="glyph">●</span>A study of 785 patients involving <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> found that a decrease of &lt;60 percent in bingeing and purging episodes by week 3 of treatment correctly identified nearly 80 percent of the patients who ultimately did not respond by week 8 [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 77 patients involving <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a> found that a decrease of &lt;50 percent in bingeing and purging episodes by week 2 of treatment correctly identified 80 to 85 percent of the patients who ultimately did not respond by week 6 [<a href="#rid34">34</a>].</p><p></p><p class="headingAnchor" id="H28628957"><span class="h1">ACUTE PHARMACOTHERAPY</span><span class="headingEndMark"> — </span>We suggest that acute pharmacotherapy for bulimia nervosa proceed according to the sequence that is described in the subsections below. Patients initially receive first-line treatment and progress through each step until they respond. The sequence of treatment is summarized and depicted in the following algorithm  (<a class="graphic graphic_algorithm graphicRef119456" href="/z/d/graphic/119456.html" rel="external">algorithm 1</a>).</p><p>Randomized trials have demonstrated that several drugs are superior to placebo for treating bulimia nervosa [<a href="#rid2">2-4,8-10</a>]. However, no placebo-controlled, head-to-head trials of active drugs have been conducted. In addition, no randomized trials have evaluated the serotonin-norepinephrine reuptake inhibitors.</p><p>Among patients with bulimia nervosa who are treated with pharmacotherapy, improvement of symptoms occurs more often than remission [<a href="#rid10">10</a>]. The potential benefits of pharmacotherapy include reduction of binge eating episodes (binges), purges, eating disorder cognitions, and comorbid psychopathology such as anxiety disorders and unipolar depressive disorders. A review of randomized trials found that among patients treated with an antidepressant, the median reduction in the frequency of bingeing and purging was nearly 70 percent [<a href="#rid5">5</a>]. By contrast, reviews and meta-analyses of randomized trials have found that remission occurs in only 20 to 32 percent of patients [<a href="#rid5">5,7,15,16</a>]. There do not appear to be any consistent baseline predictors of acute response [<a href="#rid19">19</a>].</p><p>Nearly all randomized pharmacotherapy trials have studied antidepressants, and the evidence indicates that antidepressants are efficacious [<a href="#rid2">2,4-8,10</a>]. As an example, a meta-analysis of eight randomized trials compared antidepressants with placebo in 901 patients with bulimia nervosa; active treatment included selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors (MAOIs) [<a href="#rid6">6</a>]. Improvement (reduction of baseline binge eating episodes ≥50 percent) occurred more often with antidepressants than placebo (relative risk 1.6, 95% CI 1.4-1.9). However, discontinuation of treatment due to adverse events was greater with antidepressants.</p><p>Medication combinations should generally be avoided because they have rarely been studied [<a href="#rid35">35</a>], and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> is contraindicated in bulimia nervosa. (See <a class="local">'Avoiding bupropion'</a> below.)</p><p>For patients with bulimia nervosa who do not respond to one medication and are switching to another drug, we usually cross-taper the drugs, except when switching to an MAOI. Clinicians must cautiously switch patients to or from an MAOI because drug-drug interactions can cause severe toxicity, including hypertensive crisis or serotonin syndrome. (See  <a class="medical medical_review" href="/z/d/html/1716.html" rel="external">"Switching antidepressant medications in adults"</a>.)</p><p class="headingAnchor" id="H28628912"><span class="h2">First-line</span><span class="headingEndMark"> — </span>We suggest the SSRI <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> as first-line treatment because of its efficacy for the behavioral and cognitive symptoms of bulimia nervosa, as well as its tolerability  (<a class="graphic graphic_algorithm graphicRef119456" href="/z/d/graphic/119456.html" rel="external">algorithm 1</a>) [<a href="#rid4">4,8,36,37</a>]. First-line treatment with fluoxetine is consistent with multiple practice guidelines [<a href="#rid2">2,18,38</a>].</p><p>Clinicians should prescribe <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> at an initial dose of 20 mg per day for the first week and titrate up by increments of 20 mg per day each week to a target dose of 60 mg per day, depending upon the therapeutic response, tolerability, and clinical urgency.</p><p><a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">Fluoxetine</a> is the best studied medication for bulimia nervosa in adults, but the trials have typically been small, limited by high dropout rates, and have compared fluoxetine with only placebo rather than other medications. Evidence supporting the use of fluoxetine includes a review that identified 12 randomized trials with fluoxetine and found that abstinence of symptoms occurred in 18 percent [<a href="#rid35">35</a>]. In a separate review of five randomized trials, four reported reduced bingeing and purging with fluoxetine compared with placebo [<a href="#rid4">4</a>]. In addition, the four trials found that fluoxetine improved dietary restraint, food preoccupation, and excessive concern and dissatisfaction with body weight and shape. Some trials found that fluoxetine decreased depressive symptoms, whereas other trials did not.</p><p>Multiple randomized trials have established that the target dose for <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> in bulimia nervosa is 60 mg per day, which is higher than the standard dose for major depression [<a href="#rid4">4,8,9,36,37</a>]. As an example, one randomized trial compared two doses of fluoxetine with placebo in 387 bulimia nervosa patients for eight weeks and found that the frequency of vomiting episodes decreased more in patients who received fluoxetine 60 mg per day, compared with either fluoxetine 20 mg or placebo (56 versus 29 and 5 percent) [<a href="#rid36">36</a>]. The frequency of binge-eating episodes also decreased more with fluoxetine 60 mg (67 versus 45 and 33 percent). Fluoxetine 20 mg per day was superior to placebo for reducing episodes of vomiting, but not binge eating. In addition, adverse events for the two doses of fluoxetine were comparable.</p><p><a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">Fluoxetine</a> is also first-line treatment for patients not responding adequately to psychotherapy [<a href="#rid39">39</a>]. Based upon our clinical experience, if psychotherapy provides little or no benefit, it should be discontinued as patients are switched to pharmacotherapy. If psychotherapy provides some benefit, fluoxetine should be added. </p><p>Additional information about <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p class="headingAnchor" id="H82012154"><span class="h3">Side effects</span><span class="headingEndMark"> — </span>To enhance adherence, clinicians should tell patients that side effects may emerge prior to therapeutic effects and that many side effects are transient. <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">Fluoxetine</a> and other SSRIs that are used for bulimia nervosa can cause the same side effects that commonly occur in general clinical use  (<a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Side effects'</a>.)</p><p>One common side effect of SSRIs is sexual dysfunction [<a href="#rid40">40</a>]. In females, this largely manifests as diminished libido and interference with orgasm, and for males, erectile dysfunction. However, maladaptive thoughts about body weight and shape that occur as part of bulimia nervosa can also interfere with sexual functioning. Thus, determining whether sexual dysfunction is an SSRI side effect is facilitated by assessing sexual functioning prior to pharmacotherapy. (See <a class="local">'Pretreatment assessment'</a> above.)</p><p>Based upon our clinical experience, successful treatment of bulimia nervosa often resolves sexual dysfunction that is present at baseline. Managing SSRI-induced sexual dysfunction is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1706.html" rel="external">"Sexual dysfunction caused by selective serotonin reuptake inhibitors (SSRIs): Management"</a>.)</p><p class="headingAnchor" id="H28628920"><span class="h2">Second-line</span><span class="headingEndMark"> — </span>For patients with bulimia nervosa who do not tolerate or respond to <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, second-line pharmacotherapy is another SSRI. We typically use <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, but a reasonable alternative is <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a> or <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a>  (<a class="graphic graphic_algorithm graphicRef119456" href="/z/d/graphic/119456.html" rel="external">algorithm 1</a>). SSRIs are second-line choices because they are better tolerated than third-line treatments [<a href="#rid2">2</a>]. Using SSRIs other than fluoxetine as second-line treatment is consistent with multiple practice guidelines [<a href="#rid2">2,18,38</a>].</p><p>When switching from first-line to second-line treatment, we usually cross-taper the drugs. (See  <a class="medical medical_review" href="/z/d/html/1716.html" rel="external">"Switching antidepressant medications in adults"</a>.)</p><p>Given the experience with <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, it’s reasonable to expect that <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a>, or <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a> will provide a better response at doses that are higher than the usual dose used to treat major depression [<a href="#rid41">41</a>]; the titration intervals are comparable to those used for depression  (<a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Dose'</a>.)</p><p>The SSRI <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> is typically not used for bulimia nervosa due to concerns about weight gain. (See <a class="local">'Weight change as a side effect'</a> above.)</p><p>In addition, the SSRI <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> is generally not used because of concerns about adverse cardiac effects, especially in light of electrolyte disturbances that can occur in bulimia nervosa. (See  <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Citalopram'</a> and  <a class="medical medical_review" href="/z/d/html/14728.html" rel="external">"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management", section on 'Renal and electrolytes'</a>.)</p><p>Evidence for the efficacy of <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a>, or <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a> includes small randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>Sertraline – A three-month randomized trial that compared <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> (100 mg per day) with placebo in 20 women with bulimia nervosa showed that binge eating and purging episodes decreased more with sertraline [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Escitalopram – <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">Escitalopram</a> is one of the two stereoisomers that constitute <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> and escitalopram more potently inhibits reuptake of serotonin compared with the other stereoisomer. A three-month randomized trial compared citalopram (40 mg per day) with placebo in 27 women with bulimia nervosa and found that self-rated global assessment of symptoms improved more with active drug than placebo; however, reduction in the number of bingeing and purging episodes was comparable [<a href="#rid43">43</a>]. In addition, a three-month, open-label randomized trial compared citalopram (20 to 40 mg per day) with <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> (20 to 60 mg per day) in 37 patients with bulimia nervosa, and found that improvement of the overall severity of illness was comparable for the two groups [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">Additional indirect evidence supporting the use of <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a> includes a three-month randomized trial that compared escitalopram (mean dose 27 mg per day) with placebo in 44 patients with binge eating disorder [<a href="#rid45">45</a>]. Global severity of illness improved more with escitalopram than placebo, and one analysis showed that reduction of binge eating was also greater with active drug. However, another analysis found that reduction of binge eating was comparable for escitalopram and placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fluvoxamine – A three-month randomized trial that compared <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a> (200 mg per day) with placebo in 12 women with bulimia nervosa showed that reduction of binge eating and purging episodes was greater with fluvoxamine [<a href="#rid46">46</a>].</p><p></p><p>Additional information about <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a> and <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a>, including side effects  (<a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 2</a>), is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p class="headingAnchor" id="H28628928"><span class="h2">Third-line</span><span class="headingEndMark"> — </span>For patients with bulimia nervosa who do not tolerate or respond to first- and second-line medications, we suggest third-line pharmacotherapy with tricyclic antidepressants, <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a>, MAOIs, and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>. The order of preference depends upon whether patients have a comorbid anxiety disorder or unipolar depressive disorder and whether patients have a low normal weight (eg, body mass index (<a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">calculator 1</a>) ≥18.5 and &lt;22 kg/m<sup>2</sup>).</p><p>For patients with bulimia nervosa who require third-line treatment, and who have a comorbid anxiety disorder or unipolar depressive disorder, or who have a low normal weight, our order of preference for pharmacotherapy is as follows  (<a class="graphic graphic_algorithm graphicRef119456" href="/z/d/graphic/119456.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Tricyclic antidepressants (eg, <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a> or <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a>)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">Trazodone</a></p><p class="bulletIndent1"><span class="glyph">●</span>MAOIs (eg, <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">phenelzine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a></p><p></p><p>For patients with bulimia nervosa who require third-line treatment, but do not have a comorbid anxiety disorder or unipolar depressive disorder, and do not have a low normal weight, our order of preference for pharmacotherapy is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a></p><p class="bulletIndent1"><span class="glyph">●</span>Tricyclic antidepressants</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">Trazodone</a></p><p class="bulletIndent1"><span class="glyph">●</span>MAOIs</p><p></p><p>Using tricyclics, <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a>, MAOIs, and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> for bulimia nervosa is consistent with multiple practice guidelines [<a href="#rid2">2,18,38</a>], based upon randomized trials that demonstrated their efficacy [<a href="#rid3">3-5,8,32,33,47</a>]. However, these drugs are generally third-line options because of numerous potential side effects  (<a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 2</a>) [<a href="#rid2">2-5,8,18,32,33,47</a>]. In addition, MAOIs require a tyramine-free diet; restricting food is problematic in patients with eating disorders, who typically have extensive, self-imposed dietary rules and restrictions that require treatment [<a href="#rid8">8</a>].</p><p>When switching from second-line treatment to third-line treatments, or between third-line treatments, we usually cross-taper the drugs, except when switching to an MAOI. Clinicians must cautiously switch patients to or from a MAOI because drug-drug interactions can cause severe toxicity, including hypertensive crisis or serotonin syndrome. (See  <a class="medical medical_review" href="/z/d/html/1716.html" rel="external">"Switching antidepressant medications in adults"</a>.)</p><p>The dose of tricyclics, <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a>, MAOIs, or <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> for treating bulimia nervosa is usually the same dose that is used in general clinical practice. Bulimia nervosa patients receiving these medications can expect to encounter the same side effects  (<a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 2</a>) that commonly occur in general clinical use. Additional information about tricyclics, trazodone, MAOIs, and topiramate is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/z/d/html/86265.html" rel="external">"Serotonin modulators: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">"Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"</a>.)</p><p>Evidence for the efficacy of third-line options for bulimia nervosa includes randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>Tricyclic antidepressants – A review identified seven trials that compared a tricyclic with placebo, including four that studied <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a>; the tricyclic was superior in six of the seven trials [<a href="#rid10">10</a>]. As an example, an eight-week randomized trial with 78 patients found that episodes of bingeing and purging decreased more with desipramine compared with placebo [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trazodone – A trial with 42 patients found that episodes of bingeing and purging decreased more with <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a> than placebo [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MAOIs – A review identified four trials that compared an MAOI with placebo; the MAOI was superior in three of the trials [<a href="#rid10">10</a>]. As an example, a 10-week trial in 50 patients found that episodes of bingeing decreased more with <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">phenelzine</a> than placebo [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topiramate – Two trials with a total of 129 patients each found that over 10 weeks, the frequency of bingeing and purging decreased more with <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> than placebo [<a href="#rid32">32,33,47</a>]. In both trials, body weight decreased more in patients who received topiramate compared with placebo, which is potentially problematic for patients with bulimia nervosa [<a href="#rid8">8</a>]. (See <a class="local">'Weight change as a side effect'</a> above.)</p><p></p><p>Although one randomized trial found that the anti-emetic <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> was efficacious for bulimia nervosa [<a href="#rid51">51</a>], it is generally not prescribed for this disorder.</p><p>For patients who do not respond to any of the third-line agents, we generally discontinue pharmacotherapy.</p><p class="headingAnchor" id="H2126883515"><span class="h2">Avoiding bupropion</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> can cause seizures in patients with active symptoms of bulimia nervosa and is thus contraindicated in patients with a current or prior diagnosis of bulimia nervosa (or anorexia nervosa) [<a href="#rid8">8,9,52,53</a>].</p><p class="headingAnchor" id="H3857972805"><span class="h1">MAINTENANCE PHARMACOTHERAPY</span><span class="headingEndMark"> — </span>Among acutely ill bulimia nervosa patients who respond or remit, 30 percent relapse [<a href="#rid5">5,20</a>]. Thus, most authorities continue pharmacotherapy for at least 6 to 12 months after response or remission [<a href="#rid2">2,5</a>]. The duration of maintenance pharmacotherapy will vary for each patient, depending upon the number of years the patient has been ill and the number of acute episodes and hospitalizations that have occurred. In reassessing the need for medication every 6 to 12 months, the clinician should also consider the stability of the patient’s recovery (ie, has the patient remained completely free of symptoms or have there been subsyndromal symptoms), the presence of comorbid psychopathology, and the patient’s level of psychosocial functioning. An observational study of 200 patients (mean follow-up duration of 12 years) suggests that pharmacotherapy can eventually be discontinued in many or most patients without recurrence [<a href="#rid54">54</a>].</p><p>Although maintenance treatment clearly reduces relapse, premature discontinuation is common, probably due to poor tolerability:</p><p class="bulletIndent1"><span class="glyph">●</span>One randomized trial compared maintenance <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> (60 mg per day) with placebo for up to 12 months in 150 patients who initially responded to open-label fluoxetine [<a href="#rid55">55</a>]. Relapse occurred in fewer patients who received fluoxetine compared with placebo (33 versus 51 percent). However, discontinuation of maintenance treatment due to relapse or other reasons was comparable for fluoxetine and placebo (63 and 68 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second randomized trial compared maintenance <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a> (mean dose 182 mg per day) with placebo for up to 15 weeks in 72 patients who initially responded to multimodal treatment that included open-label fluvoxamine [<a href="#rid56">56</a>]. Abstinence of bingeing was greater in patients who received fluvoxamine compared with placebo (70 versus 35 percent). However, discontinuation of maintenance treatment was greater with fluvoxamine (51 versus 14 percent).</p><p></p><p class="headingAnchor" id="H4021331231"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119119.html" rel="external">"Society guideline links: Eating disorders"</a>.)</p><p class="headingAnchor" id="H25953159"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16566.html" rel="external">"Patient education: Bulimia nervosa (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H86984499"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnostic criteria  (<a class="graphic graphic_table graphicRef91105" href="/z/d/graphic/91105.html" rel="external">table 1</a>) for bulimia nervosa include binge eating, inappropriate compensatory behavior to prevent weight gain, and self-evaluation that is unduly influenced by body weight and shape. (See  <a class="medical medical_review" href="/z/d/html/14709.html" rel="external">"Bulimia nervosa in adults: Clinical features, course of illness, assessment, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacotherapy alone appears to be less efficacious than psychotherapy alone, and combining the two appears to be the best approach. Nevertheless, pharmacotherapy is efficacious for bulimia nervosa and may be included in the initial treatment regimen, along with nutritional rehabilitation and psychotherapy. However, using pharmacotherapy alone is reasonable if specialized nutritional services or psychotherapy are not available. (See <a class="local">'Different treatments and their efficacy'</a> above and  <a class="medical medical_review" href="/z/d/html/2094.html" rel="external">"Eating disorders: Overview of prevention and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with bulimia nervosa who are treated with pharmacotherapy, we suggest <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> as first-line treatment rather than other medications  (<a class="graphic graphic_algorithm graphicRef119456" href="/z/d/graphic/119456.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The target dose is 60 mg per day. (See <a class="local">'First-line'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with bulimia nervosa who do not tolerate or respond to <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, we suggest second-line pharmacotherapy with a different selective serotonin reuptake inhibitor (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, but a reasonable alternative is <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a> or <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a>; these drugs are often prescribed at higher doses for bulimia nervosa than are used to treat major depression. (See <a class="local">'Second-line'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Third-line medication options for bulimia nervosa include other antidepressants or <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>. For patients who have a comorbid anxiety disorder or unipolar depressive disorder, or who have a low normal weight, our order of preference for pharmacotherapy is as follows: tricyclic antidepressants, <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a>, monoamine oxidase inhibitors, or topiramate. For patients who do not have a comorbid anxiety disorder or unipolar depressive disorder, and do not have a low normal weight, our order of preference is topiramate, tricyclics, trazodone, or monoamine oxidase inhibitors (See <a class="local">'Third-line'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> is contraindicated in bulimia nervosa. (See <a class="local">'Avoiding bupropion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with bulimia nervosa who receive pharmacotherapy can expect to encounter the same side effects  (<a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 2</a>) that commonly occur in general clinical use. Antidepressants in general may possibly increase the risk of suicidality in young adults, but there is no clear evidence. (See <a class="local">'Side effects'</a> above and <a class="local">'Serious side effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relapse of bulimia nervosa occurs frequently. For patients who respond to or remit with pharmacotherapy, we suggest maintenance pharmacotherapy rather than no pharmacotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Although maintenance treatment prevents relapse, premature discontinuation is common, probably due to poor tolerability.</p><p></p><p class="bulletIndent1">The duration of maintenance pharmacotherapy varies, depending upon several clinical factors. Maintenance pharmacotherapy is typically prescribed for at least 6 to 12 months beyond response or remission. (See <a class="local">'Maintenance pharmacotherapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Crow S, Mussell MP, Peterson C, et al. Prior treatment received by patients with bulimia nervosa. Int J Eat Disord 1999; 25:39.</a></li><li><a class="nounderline abstract_t">American Psychiatric Association. Treatment of patients with eating disorders,third edition. American Psychiatric Association. Am J Psychiatry 2006; 163:4.</a></li><li class="breakAll">Eating Disorders: Core Interventions in the Treatment of and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders. National Institute for Clinical Excellence, Clinical Guideline 9. http://guidance.nice.org.uk (Accessed on December 22, 2010).</li><li><a class="nounderline abstract_t">Shapiro JR, Berkman ND, Brownley KA, et al. Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40:321.</a></li><li class="breakAll">Agras WS. Treatment of eating disorders. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.1231.</li><li><a class="nounderline abstract_t">Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003; :CD003391.</a></li><li><a class="nounderline abstract_t">Nakash-Eisikovits O, Dierberger A, Westen D. A multidimensional meta-analysis of pharmacotherapy for bulimia nervosa: summarizing the range of outcomes in controlled clinical trials. Harv Rev Psychiatry 2002; 10:193.</a></li><li class="breakAll">Gianini L, Broft A, Devlin M. Treatment of binge eating, including bulimia nervosa and binge-eating disorder. In: Handbook of Assessment and Treatment of Eating Disorders, Walsh BT, Attia E, Glasofer DR, Sysko R (Eds), American Psychiatric Association Publishing, Arlington, VA 2016. p.279.</li><li class="breakAll">Agras WS. Treatment of eating disorders. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.1337.</li><li><a class="nounderline abstract_t">Flament MF, Bissada H, Spettigue W. Evidence-based pharmacotherapy of eating disorders. Int J Neuropsychopharmacol 2012; 15:189.</a></li><li><a class="nounderline abstract_t">Kaye W. Neurobiology of anorexia and bulimia nervosa. Physiol Behav 2008; 94:121.</a></li><li><a class="nounderline abstract_t">Kaye WH, Bailer UF, Frank GK, et al. Brain imaging of serotonin after recovery from anorexia and bulimia nervosa. Physiol Behav 2005; 86:15.</a></li><li><a class="nounderline abstract_t">Monteleone P, Santonastaso P, Tortorella A, et al. Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa. Mol Psychiatry 2005; 10:716.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li><a class="nounderline abstract_t">Bacaltchuk J, Hay P, Trefiglio R. Antidepressants versus psychological treatments and their combination for bulimia nervosa. Cochrane Database Syst Rev 2001; :CD003385.</a></li><li><a class="nounderline abstract_t">Bacaltchuk J, Trefiglio RP, Oliveira IR, et al. Combination of antidepressants and psychological treatments for bulimia nervosa: a systematic review. Acta Psychiatr Scand 2000; 101:256.</a></li><li><a class="nounderline abstract_t">Bacaltchuk J, Trefiglio RP, de Oliveira IR, et al. Antidepressants versus psychotherapy for bulimia nervosa: a systematic review. J Clin Pharm Ther 1999; 24:23.</a></li><li><a class="nounderline abstract_t">Hay P, Chinn D, Forbes D, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of eating disorders. Aust N Z J Psychiatry 2014; 48:977.</a></li><li><a class="nounderline abstract_t">Sysko R, Sha N, Wang Y, et al. Early response to antidepressant treatment in bulimia nervosa. Psychol Med 2010; 40:999.</a></li><li><a class="nounderline abstract_t">Keel PK, Mitchell JE. Outcome in bulimia nervosa. Am J Psychiatry 1997; 154:313.</a></li><li class="breakAll">Cooper, Z, Fairburn, CG. Cognitive behavior therapy for bulimia nervosa. In: The Treatment of Eating Disorders, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.243.</li><li><a class="nounderline abstract_t">Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl 11:37.</a></li><li class="breakAll">Labbate, LA, Fava, et al. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia, PA 2010. p.54.</li><li><a class="nounderline abstract_t">Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65:1365.</a></li><li><a class="nounderline abstract_t">Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156:1170.</a></li><li><a class="nounderline abstract_t">Croft H, Settle E Jr, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 21:643.</a></li><li><a class="nounderline abstract_t">Uher R, Farmer A, Henigsberg N, et al. Adverse reactions to antidepressants. Br J Psychiatry 2009; 195:202.</a></li><li><a class="nounderline abstract_t">de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991; 24:62.</a></li><li><a class="nounderline abstract_t">Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17:95.</a></li><li><a class="nounderline abstract_t">Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18:211.</a></li><li><a class="nounderline abstract_t">Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61:863.</a></li><li><a class="nounderline abstract_t">Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64:1335.</a></li><li><a class="nounderline abstract_t">Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005; 38:295.</a></li><li><a class="nounderline abstract_t">Walsh BT, Sysko R, Parides MK. Early response to desipramine among women with bulimia nervosa. Int J Eat Disord 2006; 39:72.</a></li><li><a class="nounderline abstract_t">Mitchell JE, Roerig J, Steffen K. Biological therapies for eating disorders. Int J Eat Disord 2013; 46:470.</a></li><li><a class="nounderline abstract_t">Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch Gen Psychiatry 1992; 49:139.</a></li><li><a class="nounderline abstract_t">Goldstein DJ, Wilson MG, Thompson VL, et al. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br J Psychiatry 1995; 166:660.</a></li><li class="breakAll">NICE National Institute for Health and Care Excellence. Eating Disorders: Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. Clinical guideline 9. January 2004. http://www.nice.org.uk/guidance/cg9/ (Accessed on June 10, 2015).</li><li><a class="nounderline abstract_t">Walsh BT, Agras WS, Devlin MJ, et al. Fluoxetine for bulimia nervosa following poor response to psychotherapy. Am J Psychiatry 2000; 157:1332.</a></li><li><a class="nounderline abstract_t">Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004; 65:959.</a></li><li class="breakAll">Mitchell JE, Wonderlich SA. Feeding and eating disorders. In: The American Psychiatric Publishing Textbook of Psychiatry, Sixth Edition, Hales RE, Yudofsky SC, Roberts LW (Eds), American Psychiatric Publishing, Washington, DC 2014. p.557.</li><li><a class="nounderline abstract_t">Milano W, Petrella C, Sabatino C, Capasso A. Treatment of bulimia nervosa with sertraline: a randomized controlled trial. Adv Ther 2004; 21:232.</a></li><li><a class="nounderline abstract_t">Sundblad C, Landén M, Eriksson T, et al. Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study. J Clin Psychopharmacol 2005; 25:85.</a></li><li><a class="nounderline abstract_t">Leombruni P, Amianto F, Delsedime N, et al. Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial. Adv Ther 2006; 23:481.</a></li><li><a class="nounderline abstract_t">Guerdjikova AI, McElroy SL, Kotwal R, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol 2008; 23:1.</a></li><li><a class="nounderline abstract_t">Milano W, Siano C, Putrella C, Capasso A. Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial. Adv Ther 2005; 22:278.</a></li><li><a class="nounderline abstract_t">Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003; 64:1449.</a></li><li><a class="nounderline abstract_t">Walsh BT, Hadigan CM, Devlin MJ, et al. Long-term outcome of antidepressant treatment for bulimia nervosa. Am J Psychiatry 1991; 148:1206.</a></li><li><a class="nounderline abstract_t">Pope HG Jr, Keck PE Jr, McElroy SL, Hudson JI. A placebo-controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol 1989; 9:254.</a></li><li><a class="nounderline abstract_t">Walsh BT, Gladis M, Roose SP, et al. Phenelzine vs placebo in 50 patients with bulimia. Arch Gen Psychiatry 1988; 45:471.</a></li><li><a class="nounderline abstract_t">Faris PL, Kim SW, Meller WH, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000; 355:792.</a></li><li class="breakAll">Wellbutrin (bupropion hydrochloride) Highlights of Prescribing Information 05/2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018644s052lbl.pdf (Accessed on September 15, 2018).</li><li><a class="nounderline abstract_t">Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49:262.</a></li><li><a class="nounderline abstract_t">Keel PK, Mitchell JE, Miller KB, et al. Long-term outcome of bulimia nervosa. Arch Gen Psychiatry 1999; 56:63.</a></li><li><a class="nounderline abstract_t">Romano SJ, Halmi KA, Sarkar NP, et al. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 2002; 159:96.</a></li><li><a class="nounderline abstract_t">Fichter MM, Krüger R, Rief W, et al. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J Clin Psychopharmacol 1996; 16:9.</a></li></ol></div><div id="topicVersionRevision">Topic 14734 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9924651" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prior treatment received by patients with bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16925191" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of patients with eating disorders,third edition. American Psychiatric Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16925191" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of patients with eating disorders,third edition. American Psychiatric Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17370288" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bulimia nervosa treatment: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17370288" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bulimia nervosa treatment: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583971" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antidepressants versus placebo for people with bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12119306" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A multidimensional meta-analysis of pharmacotherapy for bulimia nervosa: summarizing the range of outcomes in controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12119306" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A multidimensional meta-analysis of pharmacotherapy for bulimia nervosa: summarizing the range of outcomes in controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12119306" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A multidimensional meta-analysis of pharmacotherapy for bulimia nervosa: summarizing the range of outcomes in controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21414249" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evidence-based pharmacotherapy of eating disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164737" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neurobiology of anorexia and bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102788" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Brain imaging of serotonin after recovery from anorexia and bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940301" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940301" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11687197" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antidepressants versus psychological treatments and their combination for bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10782544" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Combination of antidepressants and psychological treatments for bulimia nervosa: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10319904" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antidepressants versus psychotherapy for bulimia nervosa: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25351912" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of eating disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20441691" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Early response to antidepressant treatment in bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9054777" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Outcome in bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9054777" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Outcome in bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926053" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Weight gain and antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926053" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Weight gain and antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491240" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10450256" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Changes in weight during a 1-year trial of fluoxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10363731" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19721108" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adverse reactions to antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1852793" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981349" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12817155" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11105740" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14658948" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16231337" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254873" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Early response to desipramine among women with bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23658094" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Biological therapies for eating disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1550466" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7620754" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7620754" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910801" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fluoxetine for bulimia nervosa following poor response to psychotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15291685" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15291685" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15605617" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of bulimia nervosa with sertraline: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15643104" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912031" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18058852" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236688" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14728106" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1882999" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term outcome of antidepressant treatment for bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2671058" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A placebo-controlled study of trazodone in bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3282482" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Phenelzine vs placebo in 50 patients with bulimia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711927" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711927" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3134343" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment of bulimia with bupropion: a multicenter controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892257" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term outcome of bulimia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11772696" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8834413" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
